New Treatment for Type 2 Diabetes

27th November 2013

Diabetes is a condition that has become relatively commonplace in the UK, with many lasting consequences when mismanaged or left untreated. The condition presents in one of two forms, the aptly named Type I and Type II variants of the condition are subtly different in how the normal workings of Insulin have been disrupted. In Type I the cells of the body responsible for the production of Insulin are left unable to do so, while in Type II the body's ability to meet its Insulin requirements, or the effectiveness of the Insulin produced, are lacking. Researchers in Sydney have recently developed a drug which offers a potential solution to some of the more devastating effects of the condition.

Type II Diabetes accounts for as many as 90% of instances of the condition here in the UK. These include potential blindness through Diabetic Retinopathy, neuropathic issues, heart problems, and vascular conditions which can ultimately lead to the need for amputation. The potentially life changing and catastrophic consequences of Type II Diabetes, as well as the increasing trend for diagnoses of the condition at younger ages, has created a need for more effective treatments.

Researchers at Sydney's Royal North Shore hospital have developed Invokana, a drug designed to prevent the more devastating effects of the Type II Diabetes. This particular medication is designed to block the action of a protein located in the kidney and responsible for filtering glucose back into our bloodstreams. The result is the passage of excess glucose through urination, and the prevention of the unhealthy accumulation of blood sugar which occurs as a consequence of Diabetes.

The drug is a welcome addition to the current arsenal of Diabetic treatments, and offers a viable and effect means by which to help sufferers manage the condition.